Goodgrower

Goodgrower's primary deal flow advantage is its ownership and operation of the Vithas network, which generates healthcare expansion opportunities from within. The firm's membership in the European Healthcare Investor Association and familial ties to the Spanish business establishment provide additional origination channels. Susana Gallardo's advisory role at the Universitat Internacional de Catalunya also positions the firm to identify early-stage health sciences ventures.

Goodgrower operates as a hybrid. It functions as a family investment office managing Gallardo wealth, yet it directly controls a substantial operating business — the Vithas hospital group — which generates its own revenue and requires active management. The firm sits under Landon Grupo Corporativo, the apex holding structure for the Gallardo family's assets, alongside pharmaceuticals group Almirall.

Landon Grupo Corporativo is the Gallardo family's ultimate holding entity and controls both Almirall, the publicly traded pharmaceutical company, and Goodgrower. Carlos Gallardo Piqué, brother of Goodgrower's president Jorge, leads Almirall as CEO and president. The three siblings — Jorge, Susana, and Carlos — occupy key oversight positions across the family's corporate and investment structures.

Goodgrower's recorded strategy spans growth-stage and general venture investments, alongside direct operating-company control. The Vithas hospital network represents mature, control-oriented deployment, while the firm also pursues expansion-stage healthcare services and commercial real estate development projects in Spanish metropolitan markets.